Clinical Trials
6 trialsNCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT03752398 2024-07-05
DUET-3
Xencor, Inc.
Phase 1 Completed
NCT03003637 2023-10-23
IMCISION
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT02741570 2023-09-21
CheckMate 651
Bristol-Myers Squibb
Phase 3 Completed
NCT02823574 2023-05-03
CheckMate 714
Bristol-Myers Squibb
Phase 2 Completed
NCT01986426 2018-10-03
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Completed